InflaRx (NASDAQ:IFRX – Get Free Report) and Vericel (NASDAQ:VCEL – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership.
Earnings & Valuation
This table compares InflaRx and Vericel”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| InflaRx | -$33,931.00 | -4,820.92 | -$51.63 million | ($0.39) | -2.85 |
| Vericel | $324.17 million | 9.23 | $16.52 million | $0.64 | 91.64 |
Vericel has higher revenue and earnings than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
42.4% of InflaRx shares are owned by institutional investors. 16.3% of InflaRx shares are owned by company insiders. Comparatively, 7.6% of Vericel shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares InflaRx and Vericel’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| InflaRx | N/A | -32.04% | -27.33% |
| Vericel | 10.27% | 9.09% | 6.68% |
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for InflaRx and Vericel, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| InflaRx | 1 | 2 | 5 | 1 | 2.67 |
| Vericel | 0 | 2 | 5 | 1 | 2.88 |
InflaRx presently has a consensus price target of $7.43, indicating a potential upside of 569.24%. Vericel has a consensus price target of $62.00, indicating a potential upside of 5.71%. Given InflaRx’s higher probable upside, research analysts plainly believe InflaRx is more favorable than Vericel.
Volatility & Risk
InflaRx has a beta of 2.38, suggesting that its stock price is 138% more volatile than the S&P 500. Comparatively, Vericel has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500.
Summary
Vericel beats InflaRx on 9 of the 13 factors compared between the two stocks.
About InflaRx
InflaRx N.V. is a biotechnology company that develops therapies for inflammatory and autoimmune diseases. Its research focuses on the complement system, a part of the immune system that can contribute to inflammation and tissue damage. The company’s lead antibody, vilobelimab, targets the complement protein C5a. In 2023, the U.S. Food and Drug Administration granted emergency use authorization for vilobelimab, marketed as Gohibic, for certain hospitalized adults with COVID-19. InflaRx is also investigating the drug in other inflammatory conditions.
About Vericel
Vericel Corporation is a biopharmaceutical company focused on developing and commercializing cell therapies and other treatments for serious conditions. Based in Cambridge, Massachusetts, the company markets its products primarily in the United States. Its products include MACI, an implant made from a patient’s own cultured cartilage cells used to repair certain cartilage defects in the knee, and Epicel, a cultured skin graft used to treat patients with deep burns. Vericel also commercializes NexoBrid in the United States, an enzyme-based treatment for removing dead tissue from severe thermal burns.
Receive News & Ratings for InflaRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InflaRx and related companies with MarketBeat.com's FREE daily email newsletter.
